not losing weight on 7.5 tirzepatide 10 Reasons You Are GLP-1s how was 7.5 -> 10

10/10 recommend My experience with BMG has been Amazing

Interestingly, in SURPASS-4, the overall cohort of tirzepatide users and those with 30 mg/g UACR experienced an acute dip in eGFR at 12 weeks, resembling the eGFR slope observed in trials with semaglutide and other nephroprotective drugs, such as RAAS blockers [50] and SGLT-2i [51]

What happens when you stop each medication Weight regain after stopping weight loss medications is a reality for both classes, but the dynamics differ

Certain features warrant prompt medical evaluation: Severe muscle pain or weakness , particularly if accompanied by dark urine, which may indicate rhabdomyolysis (a rare but serious condition involving muscle breakdown) Joint swelling, redness, or warmth , which could suggest inflammatory arthritis or infection (septic arthritis) Pain that significantly impairs daily activities or does not respond to simple analgesia Systemic symptoms such as fever, unexplained weight loss (beyond expected therapeutic effect), or night sweats New or worsening pain following dose escalation, which may require dose adjustment or further investigation Sudden, severe pain in the right upper abdomen , possibly with fever or jaundice, which could indicate gallbladder disease (a recognised risk with GLP-1 receptor agonists) [1] [5] Patients should also seek advice if they experience other concerning adverse effects of Ozempic, including: Persistent nausea or vomiting leading to dehydration or reduced fluid intake Symptoms of hypoglycaemia (tremor, sweating, confusion), particularly if taking Ozempic with insulin or sulphonylureas Severe abdominal pain, which may indicate pancreatitis (a known but uncommon risk with GLP-1 receptor agonists) [1] [5] Visual changes or signs of diabetic retinopathy progression For urgent concerns outside of GP hours, patients should contact NHS 111